Is it Possible to Reduce DAPT Time in Diabetic Patients?

Short-duration dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with DES is growing steadily, especially for chronic coronary syndromes. There is also some evidence regarding its use in acute coronary syndrome.

DAPT en los diabéticos

However, diabetes is a well-known risk factor for both restenosis and thrombosis, since it involves more complex and longer lesions in vessels that are generally smaller in diameter.

Researchers conducted a subanalysis of randomized studies STOPDAPT-2 and STOP-DAPT-2ACS, comparing DAPT for 30 days with ASA 81 mg and clopidogrel, and then clopidogrel monotherapy vs. DAPT for 12 months.

This subanalysis included 5997 patients. Of these, 2030 had diabetes (33.8%) and 3967 did not. 

The primary endpoint (PEP) was a composite of cardiovascular events and bleeding. The former comprised cardiovascular death, infarction, stroke, and definite stent thrombosis. The second included major and minor bleeding according to TIMI criteria.

As regards diabetic patients, 60.9% received pharmacological treatment and 14.1%, insulin.

Read also: Can We Use DAPT for 3 Months in Acute Coronary Syndrome?

After 12 months of follow-up, there were no differences neither in the PEP (3.58% for 1-month DAPT vs. 4.12% for 12-month DAPT; hazard ratio [HR]: 0.87; 95% confidence interval [CI]: 0.56-1.37; p = 0.55) nor for cardiovascular death (3.02 vs. 3.5; p = 0.7). However, those who received DAPT for 30 days experienced less bleeding compared with those who received it for 12 months (0.30% vs. 1.50% [HR: 0.20; 95% CI: 0.06 to 0.68; p = 0.01).

Conclusion

Clopidogrel as monotherapy after 1 month with DAPT, compared with 12 months of DAPT, reduced major bleeding without an increase in cardiovascular events independent of diabetes. These findings should be considered hypothesis-generating, especially in patients with acute coronary syndromes, as the results from the STOPDAPT -2 ACS Study are inconclusive.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the editorial board of SOLACI.org.

Original Title: Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention.

Reference: Ko Yamamoto, et al. J Am Coll Cardiol Intv 2023;16:19–31.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....